Published in Gene Therapy Weekly, April 20th, 2000
Dr. Pervin Anklesaria, Targeted Genetics, presented data indicating that the company's LPD (Lipid Polycation DNA) gene delivery system is capable of delivering genes systemically when delivered intravenously. Intravenous delivery of tgLPD-E1A, the company's second-generation cancer therapeutic, inhibited tumor growth in animal models of two different human tumors.
The data were presented in an abstract titled "Systemic and Local Delivery of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly